The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study
Toxicity of AZD7648 + PLD was greater than expected and antitumour activity was limited, leading to early study termination.
Authors
- Emma Jane Dean (ORCID: https://orcid.org/0000-0001-9956-257X)
- Eric T. Gangl (ORCID: https://orcid.org/0000-0001-5243-2524)
- Benedetta Lombardi
- Amanda G. Paulovich (ORCID: https://orcid.org/0000-0001-6532-6499)
- Ruth Plummer (ORCID: https://orcid.org/0000-0003-0107-1444)
- Patricia LoRusso
- Paola Marco‐Casanova (ORCID: https://orcid.org/0009-0003-4269-8988)
- Mark J. O’Connor (ORCID: https://orcid.org/0000-0003-1823-625X)
- Bharat Patel (ORCID: https://orcid.org/0000-0002-5332-1858)
- Rowan Miller (ORCID: https://orcid.org/0000-0002-2400-1716)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Lenka Oplustil O’Connor (ORCID: https://orcid.org/0000-0001-7580-1572)
- Rebecca Kristeleit (ORCID: https://orcid.org/0000-0003-3825-1326)
- Stephen McMorn
- Roman Zviezdin
Institutions
- AstraZeneca (United Kingdom) (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Yale Cancer Center (US)
- Yale University (US)
- Fred Hutch Cancer Center (US)
- AstraZeneca (South Korea) (KR)
- Newcastle upon Tyne Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1038/s41416-025-03053-x
- Citations
- 7
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 7.32
Funders
- AstraZeneca
- Fred Hutchinson Cancer Research Center
- National Cancer Institute